Recent News

Damania named UNC School of Medicine’s Vice Dean for Research

Damania named UNC School of Medicine’s Vice Dean for Research

UNC Lineberger member Blossom Damania, PhD, the co-director of the UNC Lineberger Global Oncology Program and the UNC Lineberger Virology Program, has been named the new vice dean for research at the UNC School of Medicine. She will replace Terry Magnuson, PhD, who has been named the vice chancellor for research at UNC-Chapel Hill.

Damania named UNC School of Medicine’s Vice Dean for Research - Read More…

Lineberger members go to Washington to highlight importance of research funding

Lineberger members go to Washington to highlight importance of research funding

Chad Ellis, PhD, Ben Major, PhD, and Anne-Marie Meyer, PhD, traveled to the U.S. Capitol to meet with members of the North Carolina congressional delegation and explain the impact of National Institutes of Health and National Cancer Institute funding on the lives and well-being of people in North Carolina and the country.

Lineberger members go to Washington to highlight importance of research funding - Read More…

UNC Cancer Care earns national accreditation with commendation

UNC Cancer Care earns national accreditation with commendation

UNC Hospitals' cancer program, whose flagship location is the N.C. Cancer Hospital, has earned national accreditation from the Commission on Cancer of the American College of Surgeons, with commendation in three areas: clinical research accrual, reporting of outcomes and oncology nursing care.

UNC Cancer Care earns national accreditation with commendation - Read More…

Promise of nearly a year of life on targeted drug not reality for all liver cancer patients

Promise of nearly a year of life on targeted drug not reality for all liver cancer patients

A study led by UNC Lineberger Comprehensive Cancer Center members Hanna Sanoff and Stacie Dusetzina found that the liver cancer drug sorafenib does not deliver on its promise of 11 months of longer life for some advanced liver patients, and can come with serious side effects and significant out-of-pocket costs.

Promise of nearly a year of life on targeted drug not reality for all liver cancer patients - Read More…